The Role of Adherence to Basic Pharmacotherapy of Heart Failure for Prevention of Late Adverse Events in Patients with Coronary Artery Disease and Left Ventricular Dysfunction After Surgical Revascularization of Myocardium
Aim. To determine the role of adherence to the basic drug treatment of heart failure (HF) in prevention of late major adverse events (MAEs) after isolated coronary artery bypass grafting (CABG) in patients with stable coronary artery disease (CAD) and left ventricular (LV) dysfunction at three-year...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2020-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2289 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227607260790784 |
|---|---|
| author | O. A. Yepanchintseva K. A. Mikhaliev I. V. Shklianka O. J. Zharinov B. M. Todurov |
| author_facet | O. A. Yepanchintseva K. A. Mikhaliev I. V. Shklianka O. J. Zharinov B. M. Todurov |
| author_sort | O. A. Yepanchintseva |
| collection | DOAJ |
| description | Aim. To determine the role of adherence to the basic drug treatment of heart failure (HF) in prevention of late major adverse events (MAEs) after isolated coronary artery bypass grafting (CABG) in patients with stable coronary artery disease (CAD) and left ventricular (LV) dysfunction at three-year follow-up.Material and methods. A prospective non-controlled single-center study included 125 consecutive patients with stable CAD and LV EF<50% (62±8 years; 114 [91.2%] males), after isolated CABG. At three-year follow-up MAЕs occurred in 40 (32.0%) patients. The data on pharmacotherapy at followup were obtained in 124 patients: 85 (68.6%) patients without MAEs and 39 (31.4%) patients with MAEs.Results. The enrolled sample of patients was characterized by high discharge prescription rate of renin-angiotensin system (RAS; 86.3%) blockers (angiotensin-converting enzyme inhibitors or angiotensin-II receptors blockers), beta-blockers (BBs; 97.6%) and mineralocorticoid receptors antagonists (MRAs; 79.0%), being comparable in MAEs and non-MAEs groups. The total coverage of basic HF pharmacotherapy (the combination of RAS blockers, BBs and MRAs) at discharge was 66.1%. At follow-up, about one third of patients in both groups withheld previously prescribed triple HF therapy. The MAEs were associated with more frequent withhold of previously prescribed RAS blockers, as opposed to patients without MAEs (20.5% and 7.1%, respectively; р=0.009). The majority of patients in both groups continued BBs therapy at follow-up (95.0% and 92.9%, respectively; p=0.187). Additionally, we observed the decline of MRAs intake frequency at follow-up (to 43.6% and 49.4%, respectively; p=0.547).Conclusion. During 3-year follow-up after isolated CABG, about one third of patients with stable CAD and baseline LVEF<50% interrupted triple basic HF therapy (including RAS blockers, BBs and MRAs), mainly due to decrease of RAS blockers and MRAs usage. MAEs in patients with stable CAD and baseline LVEF<50% after CABG were associated with suboptimal use and more frequent interruption of RAS blockers. |
| format | Article |
| id | doaj-art-d14846074d0e4cdd8d4e7a589d40d044 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2020-11-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-d14846074d0e4cdd8d4e7a589d40d0442025-08-23T10:00:32ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532020-11-0116567868510.20996/1819-6446-2020-10-041787The Role of Adherence to Basic Pharmacotherapy of Heart Failure for Prevention of Late Adverse Events in Patients with Coronary Artery Disease and Left Ventricular Dysfunction After Surgical Revascularization of MyocardiumO. A. Yepanchintseva0K. A. Mikhaliev1I. V. Shklianka2O. J. Zharinov3B. M. Todurov4Shupyk National Medical Academy of Postgraduate Education; Heart Institute of the Ministry of Healthcare of UkraineState Institution of Science "Research and Practical Center of Preventive and Clinical Medicine' State Administrative DepartmentHeart Institute of the Ministry of Healthcare of UkraineShupyk National Medical Academy of Postgraduate EducationHeart Institute of the Ministry of Healthcare of UkraineAim. To determine the role of adherence to the basic drug treatment of heart failure (HF) in prevention of late major adverse events (MAEs) after isolated coronary artery bypass grafting (CABG) in patients with stable coronary artery disease (CAD) and left ventricular (LV) dysfunction at three-year follow-up.Material and methods. A prospective non-controlled single-center study included 125 consecutive patients with stable CAD and LV EF<50% (62±8 years; 114 [91.2%] males), after isolated CABG. At three-year follow-up MAЕs occurred in 40 (32.0%) patients. The data on pharmacotherapy at followup were obtained in 124 patients: 85 (68.6%) patients without MAEs and 39 (31.4%) patients with MAEs.Results. The enrolled sample of patients was characterized by high discharge prescription rate of renin-angiotensin system (RAS; 86.3%) blockers (angiotensin-converting enzyme inhibitors or angiotensin-II receptors blockers), beta-blockers (BBs; 97.6%) and mineralocorticoid receptors antagonists (MRAs; 79.0%), being comparable in MAEs and non-MAEs groups. The total coverage of basic HF pharmacotherapy (the combination of RAS blockers, BBs and MRAs) at discharge was 66.1%. At follow-up, about one third of patients in both groups withheld previously prescribed triple HF therapy. The MAEs were associated with more frequent withhold of previously prescribed RAS blockers, as opposed to patients without MAEs (20.5% and 7.1%, respectively; р=0.009). The majority of patients in both groups continued BBs therapy at follow-up (95.0% and 92.9%, respectively; p=0.187). Additionally, we observed the decline of MRAs intake frequency at follow-up (to 43.6% and 49.4%, respectively; p=0.547).Conclusion. During 3-year follow-up after isolated CABG, about one third of patients with stable CAD and baseline LVEF<50% interrupted triple basic HF therapy (including RAS blockers, BBs and MRAs), mainly due to decrease of RAS blockers and MRAs usage. MAEs in patients with stable CAD and baseline LVEF<50% after CABG were associated with suboptimal use and more frequent interruption of RAS blockers.https://www.rpcardio.online/jour/article/view/2289heart failureadverse eventscoronary artery bypass graftingleft ventricular dysfunctionpharmacotherapy |
| spellingShingle | O. A. Yepanchintseva K. A. Mikhaliev I. V. Shklianka O. J. Zharinov B. M. Todurov The Role of Adherence to Basic Pharmacotherapy of Heart Failure for Prevention of Late Adverse Events in Patients with Coronary Artery Disease and Left Ventricular Dysfunction After Surgical Revascularization of Myocardium Рациональная фармакотерапия в кардиологии heart failure adverse events coronary artery bypass grafting left ventricular dysfunction pharmacotherapy |
| title | The Role of Adherence to Basic Pharmacotherapy of Heart Failure for Prevention of Late Adverse Events in Patients with Coronary Artery Disease and Left Ventricular Dysfunction After Surgical Revascularization of Myocardium |
| title_full | The Role of Adherence to Basic Pharmacotherapy of Heart Failure for Prevention of Late Adverse Events in Patients with Coronary Artery Disease and Left Ventricular Dysfunction After Surgical Revascularization of Myocardium |
| title_fullStr | The Role of Adherence to Basic Pharmacotherapy of Heart Failure for Prevention of Late Adverse Events in Patients with Coronary Artery Disease and Left Ventricular Dysfunction After Surgical Revascularization of Myocardium |
| title_full_unstemmed | The Role of Adherence to Basic Pharmacotherapy of Heart Failure for Prevention of Late Adverse Events in Patients with Coronary Artery Disease and Left Ventricular Dysfunction After Surgical Revascularization of Myocardium |
| title_short | The Role of Adherence to Basic Pharmacotherapy of Heart Failure for Prevention of Late Adverse Events in Patients with Coronary Artery Disease and Left Ventricular Dysfunction After Surgical Revascularization of Myocardium |
| title_sort | role of adherence to basic pharmacotherapy of heart failure for prevention of late adverse events in patients with coronary artery disease and left ventricular dysfunction after surgical revascularization of myocardium |
| topic | heart failure adverse events coronary artery bypass grafting left ventricular dysfunction pharmacotherapy |
| url | https://www.rpcardio.online/jour/article/view/2289 |
| work_keys_str_mv | AT oayepanchintseva theroleofadherencetobasicpharmacotherapyofheartfailureforpreventionoflateadverseeventsinpatientswithcoronaryarterydiseaseandleftventriculardysfunctionaftersurgicalrevascularizationofmyocardium AT kamikhaliev theroleofadherencetobasicpharmacotherapyofheartfailureforpreventionoflateadverseeventsinpatientswithcoronaryarterydiseaseandleftventriculardysfunctionaftersurgicalrevascularizationofmyocardium AT ivshklianka theroleofadherencetobasicpharmacotherapyofheartfailureforpreventionoflateadverseeventsinpatientswithcoronaryarterydiseaseandleftventriculardysfunctionaftersurgicalrevascularizationofmyocardium AT ojzharinov theroleofadherencetobasicpharmacotherapyofheartfailureforpreventionoflateadverseeventsinpatientswithcoronaryarterydiseaseandleftventriculardysfunctionaftersurgicalrevascularizationofmyocardium AT bmtodurov theroleofadherencetobasicpharmacotherapyofheartfailureforpreventionoflateadverseeventsinpatientswithcoronaryarterydiseaseandleftventriculardysfunctionaftersurgicalrevascularizationofmyocardium AT oayepanchintseva roleofadherencetobasicpharmacotherapyofheartfailureforpreventionoflateadverseeventsinpatientswithcoronaryarterydiseaseandleftventriculardysfunctionaftersurgicalrevascularizationofmyocardium AT kamikhaliev roleofadherencetobasicpharmacotherapyofheartfailureforpreventionoflateadverseeventsinpatientswithcoronaryarterydiseaseandleftventriculardysfunctionaftersurgicalrevascularizationofmyocardium AT ivshklianka roleofadherencetobasicpharmacotherapyofheartfailureforpreventionoflateadverseeventsinpatientswithcoronaryarterydiseaseandleftventriculardysfunctionaftersurgicalrevascularizationofmyocardium AT ojzharinov roleofadherencetobasicpharmacotherapyofheartfailureforpreventionoflateadverseeventsinpatientswithcoronaryarterydiseaseandleftventriculardysfunctionaftersurgicalrevascularizationofmyocardium AT bmtodurov roleofadherencetobasicpharmacotherapyofheartfailureforpreventionoflateadverseeventsinpatientswithcoronaryarterydiseaseandleftventriculardysfunctionaftersurgicalrevascularizationofmyocardium |